RU2530523C2 - Способ противоопухолевой иммунотерапии - Google Patents
Способ противоопухолевой иммунотерапии Download PDFInfo
- Publication number
- RU2530523C2 RU2530523C2 RU2012112032/15A RU2012112032A RU2530523C2 RU 2530523 C2 RU2530523 C2 RU 2530523C2 RU 2012112032/15 A RU2012112032/15 A RU 2012112032/15A RU 2012112032 A RU2012112032 A RU 2012112032A RU 2530523 C2 RU2530523 C2 RU 2530523C2
- Authority
- RU
- Russia
- Prior art keywords
- dcs
- patient
- tumor
- hla
- introduction
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 58
- 238000009169 immunotherapy Methods 0.000 title abstract description 12
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 68
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 56
- 239000000427 antigen Substances 0.000 claims abstract description 40
- 102000036639 antigens Human genes 0.000 claims abstract description 40
- 108091007433 antigens Proteins 0.000 claims abstract description 40
- 210000001165 lymph node Anatomy 0.000 claims abstract description 20
- 230000035800 maturation Effects 0.000 claims abstract description 18
- 238000002679 ablation Methods 0.000 claims abstract description 10
- 238000011065 in-situ storage Methods 0.000 claims abstract description 9
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 5
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 4
- 239000011886 peripheral blood Substances 0.000 claims abstract description 4
- 210000003491 skin Anatomy 0.000 claims abstract description 4
- 210000000952 spleen Anatomy 0.000 claims abstract description 4
- 210000001541 thymus gland Anatomy 0.000 claims abstract description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 33
- 210000001519 tissue Anatomy 0.000 claims description 11
- 238000011398 antitumor immunotherapy Methods 0.000 claims description 10
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 3
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 3
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 3
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 3
- 108010010378 HLA-DP Antigens Proteins 0.000 claims description 3
- 102000015789 HLA-DP Antigens Human genes 0.000 claims description 3
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 3
- 210000004700 fetal blood Anatomy 0.000 claims description 3
- 102000054766 genetic haplotypes Human genes 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 7
- 230000028993 immune response Effects 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 206010070834 Sensitisation Diseases 0.000 abstract 1
- 230000001235 sensitizing effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000011287 therapeutic dose Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 description 13
- 230000008569 process Effects 0.000 description 11
- 230000005975 antitumor immune response Effects 0.000 description 10
- 229940029030 dendritic cell vaccine Drugs 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 230000002601 intratumoral effect Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 238000002604 ultrasonography Methods 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000003872 anastomosis Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229940121896 radiopharmaceutical Drugs 0.000 description 4
- 239000012217 radiopharmaceutical Substances 0.000 description 4
- 230000002799 radiopharmaceutical effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000002725 brachytherapy Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 238000009099 neoadjuvant therapy Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 2
- 108010058607 HLA-B Antigens Proteins 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010033892 Paraplegia Diseases 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000002692 epidural anesthesia Methods 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000004754 hybrid cell Anatomy 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 206010024378 leukocytosis Diseases 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 238000002690 local anesthesia Methods 0.000 description 2
- 210000004705 lumbosacral region Anatomy 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000003448 neutrophilic effect Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 210000003049 pelvic bone Anatomy 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 2
- 208000023958 prostate neoplasm Diseases 0.000 description 2
- 238000011472 radical prostatectomy Methods 0.000 description 2
- 238000007674 radiofrequency ablation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 210000003131 sacroiliac joint Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229940021747 therapeutic vaccine Drugs 0.000 description 2
- 239000003970 toll like receptor agonist Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010214 Compression fracture Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 238000010317 ablation therapy Methods 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 208000013228 adenopathy Diseases 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 210000003164 cauda equina Anatomy 0.000 description 1
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 208000018554 digestive system carcinoma Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000004095 humeral head Anatomy 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 210000001621 ilium bone Anatomy 0.000 description 1
- 229940124669 imidazoquinoline Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 208000010555 moderate anemia Diseases 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/58—Prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2012112032/15A RU2530523C2 (ru) | 2012-03-29 | 2012-03-29 | Способ противоопухолевой иммунотерапии |
PCT/RU2012/001039 WO2013147642A1 (fr) | 2012-03-29 | 2012-12-10 | Procédé d'immunothérapie anticancéreuse |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2012112032/15A RU2530523C2 (ru) | 2012-03-29 | 2012-03-29 | Способ противоопухолевой иммунотерапии |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2012112032A RU2012112032A (ru) | 2013-10-10 |
RU2530523C2 true RU2530523C2 (ru) | 2014-10-10 |
Family
ID=49260760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012112032/15A RU2530523C2 (ru) | 2012-03-29 | 2012-03-29 | Способ противоопухолевой иммунотерапии |
Country Status (2)
Country | Link |
---|---|
RU (1) | RU2530523C2 (fr) |
WO (1) | WO2013147642A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201618291D0 (en) * | 2016-10-28 | 2016-12-14 | Bergen Teknologioverf�Ring As | Novel immunotherapeutic treatments for tumours |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2348418C2 (ru) * | 2002-12-06 | 2009-03-10 | Норсуэст Байотерапьютикс, Инк. | Введение дендритных клеток, подвергнутых частичному созреванию in vitro, для лечения опухолей |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4841794B2 (ja) * | 2000-05-12 | 2011-12-21 | ノースウエスト バイオセラピューティクス,インコーポレイティド | ヒト樹状細胞による外因性抗原のクラスi提示を増加させる方法 |
US20050214268A1 (en) * | 2004-03-25 | 2005-09-29 | Cavanagh William A Iii | Methods for treating tumors and cancerous tissues |
-
2012
- 2012-03-29 RU RU2012112032/15A patent/RU2530523C2/ru not_active IP Right Cessation
- 2012-12-10 WO PCT/RU2012/001039 patent/WO2013147642A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2348418C2 (ru) * | 2002-12-06 | 2009-03-10 | Норсуэст Байотерапьютикс, Инк. | Введение дендритных клеток, подвергнутых частичному созреванию in vitro, для лечения опухолей |
Non-Patent Citations (1)
Title |
---|
ПРОКОПОВИЧ С.К. и др. Дендритные клетки и перспективы их использования в иммунотерапии злокачественных новообразований // Онкология, 2001, N2-3, т.3., стр.126-131. MUKHERJEE S. et al. Dendritic cells infected with a vaccinia virus interleukin-2 vector secrete high levels of IL-2 and can become efficient antigen presenting cells that secrete high levels of the immunostimulatory cytokine IL-12 // Cancer Gene Ther., 2003, Aug; 10(8), abstract * |
Also Published As
Publication number | Publication date |
---|---|
WO2013147642A1 (fr) | 2013-10-03 |
RU2012112032A (ru) | 2013-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Berd et al. | Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide | |
AU2012343536B2 (en) | Immunogenic treatment of cancer | |
CN109568570B (zh) | 一种抗肿瘤疫苗复合物及制备方法、注射剂及应用 | |
KR20080091427A (ko) | 동시 화학요법 및 면역요법 | |
Appelbe et al. | Radiation-enhanced delivery of systemically administered amphiphilic-CpG oligodeoxynucleotide | |
Aiken et al. | Atim-33. Interim results of a phase II multi-center study of oncolytic adenovirus Dnx-2401 with pembrolizumab for recurrent glioblastoma; captive study (Keynote-192) | |
US10278992B2 (en) | Therapy and methods for introducing immature and dendritic cells and/or cytotoxic T lymphocyte and anti-TNF antibody for treatment of tumors | |
RU2530523C2 (ru) | Способ противоопухолевой иммунотерапии | |
Yamazaki et al. | Boosting CAR T cell expansion and therapeutic activity with low-dose radiation therapy | |
JP2024506914A (ja) | がんの処置のための多重免疫療法とがんワクチンとを組み合わせた治療用組成物及び方法 | |
Zhang et al. | Thermal ablation versus conventional regional hyperthermia has greater anti-tumor activity against melanoma in mice by upregulating CD4+ cells and enhancing IL-2 secretion | |
AU2003277641B2 (en) | Remedy for cancer | |
Das et al. | Immunotherapeutic treatment strategies for primary brain tumors | |
US10905715B2 (en) | Autologous implantation of chimeric murine-human tumors, generated in PDX mice, for ativation of an anti-tumor immune response in the donor patient | |
Mastrangelo et al. | Cellular vaccine therapies for cancer | |
CN115969974B (zh) | 一种异黑素类仿生纳米粒和制备方法及其在原位胶质母细胞瘤光热免疫治疗中的应用 | |
KR20190011179A (ko) | 광열 처리된 세포 용해물을 유효성분으로 함유하는 백신 또는 면역치료제 조성물 | |
KR100522526B1 (ko) | 면역 치료용 수지상 세포의 제조방법 | |
Demierre et al. | Vaccine therapy of melanoma: an update | |
KR100530576B1 (ko) | 수지상세포를 이용한 암 면역 치료방법 | |
Irie et al. | Immunotherapy of melanoma: current status and prospects for the future | |
He et al. | Anti-tumor immune responses in immune-reconstituted mice injected with a tumor vaccine | |
CN115364204A (zh) | 个体化抗癌主动免疫的综合调动及抗癌免疫力的监测 | |
RU2376033C1 (ru) | Способ иммунотерапии костно-мозговыми предшественниками дендритных клеток, сенсибилизированных фотомодифицированными опухолевыми клетками in vivo, больных диссеминированными солидными опухолями | |
US20030082136A1 (en) | Anti-tumor vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20140330 |